華檢醫療(01931.HK)中期歸母淨利下降87.2%至3828.1萬元 中期息1.672港仙
格隆匯 8 月 21日丨華檢醫療(01931.HK)發佈公告,截至2020年6月30日止六個月,實現收益9.81億元(人民幣,下同),同比上升7.5%;毛利1.94億元,同比下降9.8%;母公司擁有人應占溢利3828.1萬元,同比下降87.2%;母公司擁有人應占經調整溢利6386.3萬元,同比下降39.3%;基每股盈利本2.87分;擬中期股息每股1.672港仙。
報告期內,集團實現收益較2019年同期增長7.5%,有關增長主要是由於2019年1月,公司完成對威士達60%股權的收購後,集團將威士達醫療有限公司與其附屬公司截至2020年6月30日止六個月的業績全面合併入賬,而於收購事項完成前,威士達集團於截至2019年1月31日止月度的業績並未於集團截至2019年6月30日止六個月的業績合併入賬;及自2020年年初以來,中國內地為應對新型冠狀病毒疫情而關閉醫院及採取其他檢疫及社會隔離措施,導致終端客户對體外診斷產品(“IVD”)的需求暫時減少。
此外,與2019年同期相比,集團期內的溢利大幅下降87.8%。該大幅減少主要歸因於重新計量與收購事項相關的威士達先前股權的一次性非經營性收益,反映在集團2019年同期的溢利中,但於報告期內的集團利潤中並無本項收益;如上文所述,COVID-19對集團IVD產品分銷業務的盈利能力產生不利影響;及有關購股權的開支達2558.2萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.